Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
Preexisting antibodies to endemic coronaviruses (CoV) that cross-react with SARS-CoV-2 have the potential to influence the antibody response to COVID-19 vaccination and infection for better or worse. In this observational study of mucosal and systemic humoral immunity in acutely infected, convalescent, and vaccinated subjects, we tested for cross-reactivity against endemic CoV spike (S) protein at subdomain resolution. Elevated responses, particularly to the β-CoV OC43, were observed in all natural infection cohorts tested and were correlated with the response to SARS-CoV-2. The kinetics of this response and isotypes involved suggest that infection boosts preexisting antibody lineages raised against prior endemic CoV exposure that cross-react. While further research is needed to discern whether this recalled response is desirable or detrimental, the boosted antibodies principally targeted the better-conserved S2 subdomain of the viral spike and were not associated with neutralization activity. In contrast, vaccination with a stabilized spike mRNA vaccine did not robustly boost cross-reactive antibodies, suggesting differing antigenicity and immunogenicity. In sum, this study provides evidence that antibodies targeting endemic CoV are robustly boosted in response to SARS-CoV-2 infection but not to vaccination with stabilized S, and that depending on conformation or other factors, the S2 subdomain of the spike protein triggers a rapidly recalled, IgG-dominated response that lacks neutralization activity.
Top-30
Citations by journals
1
2
3
4
|
|
Viruses
4 publications, 13.79%
|
|
Nature Communications
3 publications, 10.34%
|
|
Vaccines
2 publications, 6.9%
|
|
Frontiers in Immunology
2 publications, 6.9%
|
|
iScience
1 publication, 3.45%
|
|
Virology Journal
1 publication, 3.45%
|
|
Libyan Journal of Medicine
1 publication, 3.45%
|
|
Open Forum Infectious Diseases
1 publication, 3.45%
|
|
FEBS Journal
1 publication, 3.45%
|
|
Russian Journal of Infection and Immunity
1 publication, 3.45%
|
|
Cellular and Molecular Immunology
1 publication, 3.45%
|
|
Journal of Allergy and Clinical Immunology Global
1 publication, 3.45%
|
|
Influenza and other Respiratory Viruses
1 publication, 3.45%
|
|
Science Translational Medicine
1 publication, 3.45%
|
|
Russian Chemical Reviews
1 publication, 3.45%
|
|
Trends in Immunology
1 publication, 3.45%
|
|
1
2
3
4
|
Citations by publishers
1
2
3
4
5
6
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
6 publications, 20.69%
|
|
Springer Nature
5 publications, 17.24%
|
|
Cold Spring Harbor Laboratory
4 publications, 13.79%
|
|
Elsevier
3 publications, 10.34%
|
|
Frontiers Media S.A.
2 publications, 6.9%
|
|
Wiley
2 publications, 6.9%
|
|
Taylor & Francis
1 publication, 3.45%
|
|
Oxford University Press
1 publication, 3.45%
|
|
Saint Petersburg Pasteur Institute
1 publication, 3.45%
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 3.45%
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.45%
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.